3-Fluoro-4-[6-methoxy-7-(1-morpholin-4-ylpropoxy)quinolin-4-yl]oxyaniline

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 3-Fluoro-4-[6-methoxy-7-(1-morpholin-4-ylpropoxy)quinolin-4-yl]oxyaniline
• 英文别名: 3-fluoro-4-[6-methoxy-7-(1-morpholin-4-ylpropoxy)quinolin-4-yl]oxyaniline
• 化学式: C₂₃H₂₆FN₃O₄
• 分子量: 427.5
• InChiKey: UUBFYMTUCFCVTJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  31
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  79.1
• 氢给体数：
  1
• 氢受体数：
  8

文献信息

• HETEROCYCLIC PYRIDONE COMPOUND, AND INTERMEDIATE, PREPARATION METHOD AND USE THEREOF
  申请人：Cheng Jianjun

  公开号：US20140206679A1

  公开（公告）日：2014-07-24

  The present invention relates to a heterocyclic pyridone compound represented by General Formula (I), where the heterocyclic pyridone compound is used as a tyrosine kinase inhibitor, and particularly a c-Met inhibitor. The present invention also relates to intermediates for preparing heterocyclic pyridone compound and a preparation method. The present invention further relates to a pharmaceutical composition containing the heterocyclic pyridone compound as an active ingredient, and a use of the pharmaceutical composition in treatment of diseases associated with tyrosine kinase c-Met, especially cancer associated with c-Met, as a medicament.

  本发明涉及一种由通式(I)表示的杂环吡啶酮化合物，其中该杂环吡啶酮化合物用作酪氨酸激酶抑制剂，特别是c-Met抑制剂。本发明还涉及用于制备杂环吡啶酮化合物的中间体和制备方法。本发明还涉及一种包含杂环吡啶酮化合物作为活性成分的药物组合物，以及药物组合物在治疗与酪氨酸激酶c-Met相关的疾病，特别是与c-Met相关的癌症作为药物的用途。
• US9562060B2
  申请人：——

  公开号：US9562060B2

  公开（公告）日：2017-02-07